• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Covetrus Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

    5/5/22 4:01:00 PM ET
    $CVET
    Other Pharmaceuticals
    Health Care
    Get the next $CVET alert in real time by email

    Covetrus Ascend builds on existing technology portfolio with addition of comprehensive functionality without the constraints of a traditional hardware system.

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today introduced Ascend—a powerful, cloud-based Practice Management software (PMS) built to enable veterinary practices across the United Kingdom, EMEA and Asia Pacific. Ascend improves efficiency, streamlines internal communication and collaboration, and creates a better experience for staff and clients.

    In today's high-demand environment, the introduction of Ascend addresses a clear and spoken technological need amongst the veterinary community. In a recent joint Covetrus and Vet Times survey, 76 percent of respondents expressed a desire for a better PMS that is easier-to-use and saves time.1

    "At Covetrus, we are constantly listening to our customers and striving to address their needs through innovative technologies that fit seamlessly into their day-to-day operations," said Georgia Wraight, Executive Vice President and President of Global Technology Solutions at Covetrus. "Ascend's user-friendly, cloud platform was designed using customer insights and feedback, combined with Covetrus' technological and industry expertise. With Ascend, we are thrilled to provide a one-stop shop on an intuitive platform that offers unparalleled functionality, along with the freedom to work from anywhere, at any time, on any device."

    Ascend offers a highly visual, dynamic interface that brings multiple systems together into one user-friendly platform - enabling stronger and better internal collaboration, as well as the ability to leverage the power of preferred third-party integrations, from scheduling and diagnostics, to billing and insurance, retail sales, and beyond.

    "We chose Covetrus technology because they're well-known and trusted for their expertise and quality in the practice management space," said Emily Renton, Clinical Director, Veterinarian and Ascend User. "Ascend is an obvious choice for us and perfect for independent practices looking for a simple system that is intuitive, well-designed and knows how to make a vet's life easier during the working day. I am so impressed with everything from the visuals, its integrations, how it helps us deal with clients in a smooth manner and how it's all tied together. It certainly makes for a happier workforce and better collaboration between my staff."

    The introduction of Ascend comes on the heels of the successful beta period of Covetrus Pulse™, an innovative cloud-based veterinary operating system (vOS) in the United States and Canada that unites the best of Covetrus' technologies into an all-in-one cloud platform. Covetrus Ascend, like Pulse, is part of Covetrus' ongoing mission to be the premier provider of ‘Connected Care' solutions designed to empower veterinarians with care management technologies that help to streamline workflows, save time, and improve outcomes. Worldwide, approximately 28,000 practices are using Covetrus PMS and Prescription Management technology. With over 30+ years of experience in delivering innovative solutions for veterinarians across the globe, Ascend is another example of the Covetrus commitment to support and empower veterinarians from the front desk to the exam room, and beyond.

    About Covetrus

    Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,700 employees serving over 100,000 customers around the globe. For more information about Covetrus, please visit Covetrus | Veterinary Software and Prescription Management Solutions.

    Forward-Looking Statements

    This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

    1 Source: Vet Times + Covetrus Survey (437 surveyed and 90 respondents carried out across the UK), March 2022

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005902/en/

    Get the next $CVET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVET

    DatePrice TargetRatingAnalyst
    6/13/2022$22.00Buy → Hold
    Stifel
    5/23/2022Outperform → Mkt Perform
    Raymond James
    11/18/2021$19.00Equal-Weight
    Morgan Stanley
    11/5/2021$37.00 → $27.00Outperform
    Raymond James
    8/9/2021$46.00 → $38.00Overweight
    Barclays
    8/6/2021$38.00 → $37.00Outperform
    Raymond James
    8/5/2021$29.00Neutral
    Credit Suisse
    7/12/2021$30.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $CVET
    SEC Filings

    See more
    • SEC Form 15-12G filed by Covetrus Inc.

      15-12G - COVETRUS, INC. (0001752836) (Filer)

      10/24/22 11:12:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Covetrus Inc.

      S-8 POS - COVETRUS, INC. (0001752836) (Filer)

      10/13/22 11:19:58 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

      SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:17:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:50:30 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/25/22 12:15:30 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/20/22 8:00:28 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:44:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Helton Sandra L returned 38,095 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:08:02 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Laskawy Philip A returned 15,064 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:42 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

      NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

      10/13/22 5:50:00 PM ET
      $CVET
      $MLKN
      $SPGI
      $WLK
      Other Pharmaceuticals
      Health Care
      Office Equipment/Supplies/Services
      Consumer Discretionary
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Covetrus downgraded by Stifel with a new price target

      Stifel downgraded Covetrus from Buy to Hold and set a new price target of $22.00

      6/13/22 7:15:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus downgraded by Raymond James

      Raymond James downgraded Covetrus from Outperform to Mkt Perform

      5/23/22 7:13:08 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Morgan Stanley initiated coverage on Covetrus with a new price target

      Morgan Stanley initiated coverage of Covetrus with a rating of Equal-Weight and set a new price target of $19.00

      11/18/21 8:28:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Financials

    Live finance-specific insights

    See more
    • Covetrus Announces Financial Results for Second Quarter of 2022

      Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

      8/4/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

      4/29/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

      Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

      2/24/22 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Leadership Updates

    Live Leadership Updates

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Margie B. Pritchard General Counsel

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

      8/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care